Search results
Results from the WOW.Com Content Network
Advisers to the U.S. Food and Drug Administration on Tuesday backed an approval for Abbott Laboratories' heart valve repair device that is designed for patients who are at risk of complications or ...
(Reuters) -Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device for patients with a potentially fatal heart disease, just months after rival Edwards ...
Conducted at 31 medical centers in the U.S., Canada and Europe, the study followed 1,014 eligible patients implanted with the Trifecta valve between 2007 and 2009 as part of a U.S. Food and Drug ...
The Food and Drug Administration Modernization Act of 1997 (Public Act 105-115) [4] amended the Food, Drug and Cosmetic Act and the Public Health Service Act to require that the NIH create and operate a public information resource, which came to be called ClinicalTrials.gov, tracking drug efficacy studies resulting from approved Investigational ...
[31] [32] It was the first aortic valve device to receive FDA approval, in November 2011 for use in inoperable patients and in October 2012 for use in patients at high surgical risk. [33] The device is effective in improving functioning in patients with severe aortic stenosis.
Compared to patients who need open heart surgery, patients who received mitral clip have less need for a blood transfusion and have fewer ventilation days. [4] When compared to the patient who has had open heart surgery, MitraClip was cheaper - approximately $2200 less per person - and the median stay in the hospital post mitral clip is 2.4 days.
The FDA alerted healthcare providers about the potential for clip lock malfunctions with Abbott Laboratories (NYSE: ABT) MitraClip's delivery system to stop heart valve leakage. "These events ...
Edwards introduced the transcatheter heart valve (THV) replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. [24] The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery ...